199 related articles for article (PubMed ID: 20510085)
1. [Value of (18)F-FDG imaging and serum tumor markers in the diagnosis of recurrent endometrial carcinoma].
Wang Q; Hong L; Wang JL; Yue MG; Li HB; Li Y
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):300-3. PubMed ID: 20510085
[TBL] [Abstract][Full Text] [Related]
2. The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker.
Ozcan Kara P; Kara T; Kaya B; Kara Gedik G; Sari O
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):257-60. PubMed ID: 23067527
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
4. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
[TBL] [Abstract][Full Text] [Related]
5. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
6. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET in the management of endometrial cancer.
Chao A; Chang TC; Ng KK; Hsueh S; Huang HJ; Chou HH; Tsai CS; Yen TC; Wu TI; Lai CH
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):36-44. PubMed ID: 16167154
[TBL] [Abstract][Full Text] [Related]
9. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
10. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
11. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
12. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
Yun M; Choi HS; Yoo E; Bong JK; Ryu YH; Lee JD
J Nucl Med; 2005 Jun; 46(6):953-7. PubMed ID: 15937305
[TBL] [Abstract][Full Text] [Related]
13. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1081-8. PubMed ID: 18180917
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma.
Belhocine T; De Barsy C; Hustinx R; Willems-Foidart J
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1132-9. PubMed ID: 12192557
[TBL] [Abstract][Full Text] [Related]
15. [The diagnostic value of FDG coincidence imaging combined with serum tumor marker assays for pulmonary lesions].
Yang JG; Li CL; Gong M; Zou LF
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):683-5. PubMed ID: 17274375
[TBL] [Abstract][Full Text] [Related]
16. Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease.
Ryu SY; Kim K; Kim Y; Park SI; Kim BJ; Kim MH; Choi SC; Lee ED; Lee KH; Kim BI
J Korean Med Sci; 2010 Jul; 25(7):1029-33. PubMed ID: 20592894
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-Fluorodeoxyglucose uptake and clinicopathological features of recurrent or metastatic endometrial stromal sarcoma.
Inoue K; Tsubamoto H; Kawata S; Hao H; Ikeda Y; Oku N; Hirota S
J Obstet Gynaecol Res; 2014 Feb; 40(2):576-82. PubMed ID: 24118160
[TBL] [Abstract][Full Text] [Related]
18. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level.
Fularz M; Adamiak P; Czepczyński R; Jarząbek-Bielecka G; Rewers A; Kędzia W; Ruchała M
Nuklearmedizin; 2015; 54(4):158-62. PubMed ID: 26076719
[TBL] [Abstract][Full Text] [Related]
19. [Clinical impact of FDG-PET in patients with suspected recurrent ovarian cancer].
Cuenca Cuenca JI; Borrego Dorado I; Vázquez Albertino R; Gómez Camarero P; Sanz Viedma S; Fernández López R
Rev Esp Med Nucl; 2008; 27(6):411-7. PubMed ID: 19094899
[TBL] [Abstract][Full Text] [Related]
20. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
